× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.

meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En Fr

Our approach

more details ...

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Interactive explorer of NMA results

Click on treatment name to display related network evidence

T vs. C	corticosteroids	remdesivir	convalescent plasma treatment	baricitinib	tofacitinib	casirivimab/imdevimab (Ronapreve)	interferon	tocilizumab	sarilumab	control
corticosteroids	---	1.05 0.87; 1.27	0.96 0.85; 1.09	1.19 1.01; 1.40	1.87 0.56; 6.23	1.19 0.99; 1.43	0.84 0.67; 1.05	1.09 0.94; 1.25	1.03 0.59; 1.79	0.92 0.84; 1.00
remdesivir	0.95 0.79; 1.16	---	0.92 0.76; 1.11	1.13 0.91; 1.41	1.79 0.53; 5.99	1.14 0.90; 1.44	0.80 0.61; 1.05	1.04 0.84; 1.27	0.98 0.55; 1.74	0.88 0.74; 1.04
convalescent plasma treatment	1.04 0.92; 1.18	1.09 0.90; 1.32	---	1.23 1.05; 1.46	1.95 0.59; 6.47	1.24 1.03; 1.49	0.87 0.70; 1.09	1.13 0.98; 1.30	1.07 0.62; 1.86	0.95 0.87; 1.04
baricitinib	0.84 0.71; 0.99	0.88 0.71; 1.10	0.81 0.69; 0.96	---	1.58 0.47; 5.27	1.00 0.81; 1.24	0.71 0.55; 0.91	0.91 0.76; 1.09	0.87 0.49; 1.52	0.77 0.67; 0.89
tofacitinib	0.53 0.16; 1.78	0.56 0.17; 1.88	0.51 0.15; 1.71	0.63 0.19; 2.12	---	0.64 0.19; 2.13	0.45 0.13; 1.52	0.58 0.17; 1.93	0.55 0.15; 2.05	0.49 0.15; 1.62
casirivimab/imdevimab (Ronapreve)	0.84 0.70; 1.01	0.88 0.70; 1.11	0.81 0.67; 0.97	1.00 0.81; 1.23	1.57 0.47; 5.26	---	0.71 0.54; 0.92	0.91 0.75; 1.11	0.86 0.49; 1.53	0.77 0.66; 0.90
interferon	1.19 0.95; 1.49	1.25 0.95; 1.63	1.14 0.91; 1.43	1.41 1.10; 1.81	2.23 0.66; 7.51	1.42 1.09; 1.84	---	1.29 1.02; 1.63	1.22 0.68; 2.19	1.09 0.89; 1.34
tocilizumab	0.92 0.80; 1.06	0.97 0.79; 1.18	0.89 0.77; 1.03	1.09 0.91; 1.31	1.72 0.52; 5.75	1.10 0.90; 1.34	0.77 0.61; 0.98	---	0.95 0.54; 1.66	0.85 0.75; 0.95
sarilumab	0.97 0.56; 1.69	1.02 0.57; 1.80	0.93 0.54; 1.62	1.15 0.66; 2.02	1.82 0.49; 6.78	1.16 0.65; 2.04	0.82 0.46; 1.46	1.05 0.60; 1.84	---	0.89 0.52; 1.54
control	1.09 1.00; 1.19	1.14 0.96; 1.35	1.05 0.96; 1.15	1.29 1.13; 1.49	2.04 0.62; 6.76	1.30 1.11; 1.53	0.92 0.75; 1.13	1.18 1.05; 1.33	1.12 0.65; 1.94	---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy -